Yahoo Finance • 11 months ago
Verona Pharma plc Strengthens financial flexibility to support the Company’s continued growth LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-own... Full story
Yahoo Finance • 11 months ago
Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task. Three Motley Fool contributors think they've identified stocks that could be... Full story
Yahoo Finance • last year
LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards... Full story
Yahoo Finance • last year
In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest eco... Full story
Yahoo Finance • last year
Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today SAN DIEGO, November 08, 2023--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporate... Full story
Yahoo Finance • last year
LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the following conferences in November 20... Full story
Yahoo Finance • last year
On November 3, 2023, Kathleen Rickard, the Chief Medical Officer of Verona Pharma PLC (NASDAQ:VRNA), sold 58,752 shares of the company. This move is part of a series of transactions made by the insider over the past year, which have seen a... Full story
Yahoo Finance • last year
US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference call today at 9:00 a.m. EDT / 1:00 p.m.... Full story
Yahoo Finance • last year
LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report it... Full story
Yahoo Finance • last year
LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City for investors and analysts on Wednesday, October... Full story
Yahoo Finance • last year
PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Oct. 03, 2023 (GLOBE... Full story
Yahoo Finance • last year
PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade LONDON and RALEIGH, N.C., Sept. 11, 2023 (GLOBE NEWS... Full story
Yahoo Finance • last year
LONDON and RALEIGH, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with e... Full story
Yahoo Finance • last year
LONDON and RALEIGH, N.C., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director. Ms. Ackerman... Full story
Yahoo Finance • last year
LONDON and RALEIGH, N.C., June 28, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the American Journal of Respiratory and Critical Care Medicine (“AJRCCM”) has published results fr... Full story
Yahoo Finance • last year
LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for... Full story
Yahoo Finance • 2 years ago
NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support commercial launch preparations Conferen... Full story
Yahoo Finance • 2 years ago
12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST LONDON and RALEIGH, N.C., May 02, 2023 (GLOB... Full story
Yahoo Finance • 2 years ago
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report i... Full story
Yahoo Finance • 2 years ago
Verona Pharma plc (NASDAQ:VRNA) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and com... Full story